Rejections under 35 U.S.C.§ 112

Claims 1, 20 and 25-27 are rejected under 35 U.S.C.§ 112, first paragraph, as containing subject matter which was not described in such a way as to enable one skilled in the art to make and use the invention, specifically, the examiner maintained that use of one cell line (page 11 of the specification) in the in vitro assay is not enough to substantiate the claim of treating or inhibiting angiogenesis or cancer as claimed. Applicants respectfully traverse and request withdrawal of the same. Applicants have taught how to make the compounds of the invention and described an assay for testing the same. It is well established in the literature that inhibition of the migration of the human microvascular endothelial cells inhibits angiogenesis. There is no requirement for a patentee to use multiple cell lines in order to enable an invention. Claims 26 and 27 have been cancelled.

Claims 1, 20 and 25-27 are rejected under 35 U.S.C.§ 112, second paragraph. The examiner noted that the term "effective" amount in claim 1 is not clearly connected to the inhibition of angiogenesis. Applicants respectfully traverse and request withdrawal of the same. Applicants have deleted the term "therapeutically effective amount of" from claims 1, 25, 31 and 32.

In view of the amendments and remarks, applicants respectfully maintain that the rejections are now moot and request their withdrawal.

ACTION REQUESTED

In view of the amendments and the aforementioned remarks, Applicants believe that the application is in condition for allowance and respectfully request that the Examiner withdraw all outstanding rejections and passes this application to allowance. Should the Examiner have any concerns regarding the above, he is respectfully requested to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Haviv, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623



Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants